Drug Interactions between benzgalantamine and Vonjo

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Pacritinib can cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. In a 24-week study of 54 patients with myelofibrosis treated with pacritinib 200 mg twice daily, the largest mean (90% confidence interval [CI]) increase in QTcF was 11 msec (90% CI: 5 to 17 msec). In clinical trials, QTc prolongation >500 msec and QTc increase of at least 60 msec over baseline were higher in pacritinib-treated patients (1.4% and 1.9%, respectively) than in control arm patients (1% and 1%, respectively). In addition, QTc prolongation was reported for 3.8% of pacritinib-treated patients and 2% of control arm patients. No cases of torsades de pointes were reported. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia, hypocalcemia). Moreover, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s).

MANAGEMENT: Concomitant use of pacritinib with drugs that have significant potential for QTc prolongation should be avoided. An electrocardiogram should be obtained prior to initiating pacritinib therapy and as clinically indicated during treatment. Correct hypokalemia before and during treatment. In addition to electrolyte management, pacritinib treatment should be interrupted and the dosage reduced based on severity of QT prolongation in accordance with product labeling. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.